Acrivon Therapeutics (NASDAQ: ACRV) has announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory, located on premises in Watertown, Massachusetts.
According to Acrivon, the CLIA-certified facility is expected to be fully operational during the first half of 2026.
In a statement, Peter Blume-Jensen, MD, PhD, CEO, president and co-founder of Acrivon, commented, “We are excited to bring our cutting-edge CLIA lab online, expanding our targeted therapeutics development capabilities. Complementing our distinctive AP3-driven biomarker discovery technology, our internal CLIA lab enables us to translate these discoveries and deploy proprietary companion diagnostics for our therapeutics with minimal dependency on outside partners.”
